14th week of 2014 patent applcation highlights part 34 |
Patent application number | Title | Published |
20140093443 | STORAGE MATERIAL AND METHOD FOR OBTAINING H-SILANES THEREFROM - A storage material for obtaining H-silanes which is present in the form of a hydrogenated polysilane (HPS), as a pure compound or as a mixture of compounds having on average at least six direct Si—Si bonds, the substituenis of which predominantly consist of hydrogen and in the composition of which the atomic ratio of sabstitueot to silicon is at least 1:1. | 2014-04-03 |
20140093444 | Process for Ammonia Saturation of Solid Materials, and Corresponding Assembly - A process for ammonia saturation of a solid material capable of absorbing and desorbing ammonia, the solid material being composed of solid particles and includes placing the solid material in contact with a cooled surface, with the solid material being disposed against the cooled surface in a thin layer having a thickness of less than 100 mm. The process further includes injecting a stream of gaseous ammonia to be in contact with the solid material, while the solid material is in contact with the cooled surface. | 2014-04-03 |
20140093445 | Environmentally friendly system and method for manufacturing iron powder - High-purity iron powder products produced by a low-temperature process by feeding hematite and a reducing agent into a rotary reactor under pressure to form a mechanical fluid bed. The fluid bed is rotated at a particular speed within a rotary reactor. The fluid bed is simultaneously heated to a reaction temperature, and the pressure is then reduced within the rotary reactor to a pressure in a range of 0.01 bars to 2.0 bars, as a result reducing the reaction temperature to a temperature in a range of 600° C. to 850° C. Maintaining the pressure and the rotation results in the formation of a high-purity iron oxide without the requirement for post-grinding process steps because sintering is prevented by using a combination of pressure reduction and a rotary set at an optimum rotation speed, resulting in useful additives produced by a more environmentally-friendly process. | 2014-04-03 |
20140093446 | METHODS, SYSTEMS, AND DEVICES FOR SYNTHESIS GAS RECAPTURE - Methods, systems, and/or devices for synthesis gas recapture are provided, which may include methods, systems, and/or devices for filtering a synthesis gas stream. In some cases, tars, particulates, water, and/or heat may be removed from the synthesis gas stream through the filtering of the synthesis gas stream. The filtered synthesis gas stream may then be captured and/or utilized in a variety of different ways. Some embodiments utilizing a C—O—H compound to filter a synthesis gas stream. In some embodiments, the C—O—H compound utilized to filter the synthesis gas stream may be utilized to produce additional synthesis gas. The additional synthesis gas may be filtered by additional C—O—H compound. | 2014-04-03 |
20140093447 | System and Method for Using Board Plant Flue Gases in the Production of Syngas - Disclosed is an apparatus and method for capturing the hot humid gases from a gypsum board dryer and utilizing those gases in the production of a synthetic gas (referred to as “syngas”). The syngas produced can then be utilized within a gypsum board plant to reduce the amount of natural gas needed. The method utilizes the heated water vapor (H | 2014-04-03 |
20140093448 | MOLECULAR SIEVES AND RELATED METHODS AND STRUCTURE DIRECTING AGENTS - Method for preparing molecular sieves and molecular sieves obtained thereby are described. The method includes preparing a reaction mixture, comprising a structure directing agent, at least one source of at least one oxide of a tetravalent element, optionally, one or more sources of one or more oxides selected from the group consisting of oxides of trivalent elements, pentavalent elements, and mixtures thereof, optionally, at least one source of an element selected from Groups 1 and 2 of the Periodic Table; and optionally, hydroxide ions or fluoride ions, and maintaining the reaction mixture under conditions sufficient to form crystals of the molecular sieve. In the method, various imidazolium cations are used as the structure directing element. | 2014-04-03 |
20140093449 | Method for Preparing Largazole Analogs and Uses Thereof - Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described. | 2014-04-03 |
20140093450 | PRETARGETING KIT FOR IMAGING OR THERAPY COMPRISING A TRANS-CYCLOOCTENE DIENOPHILE AND A DIENE - Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds. | 2014-04-03 |
20140093451 | Coupled identification and treatment of cancer - Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition. | 2014-04-03 |
20140093452 | Magnetic Resonance Imaging Cell Labeling Methods and Compositions - The disclosure provides, in part, fluorocarbon imaging reagents and methods for image-guided treatment and/or diagnosis of a subject with a condition associated with an inflammatory response in an internal organ. The disclosure additionally provides methods for image-guided treatment of myocardial infarction (MI) in a subject. | 2014-04-03 |
20140093453 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS - The present invention relates to the compound of formula (I): | 2014-04-03 |
20140093454 | Human Monoclonal Antibodies Against CD20 - Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2014-04-03 |
20140093455 | METHOD FOR TREATING AND CONFIRMING DIAGNOSIS OF EXERTIONAL COMPARTMENT SYNDROME - Described is a new method of treating chronic compartment syndrome in a muscle of a mammal, particularly exertional compartment syndrome. The method includes introducing an effective amount of a nerve-blocking toxin, such as human botulinum toxin into the muscle. Further in addition to treating chronic or exertional compartment syndrome, a method is included and described in the disclosure of confirming diagnosis of exertional compartment syndrome in a muscle of a mammal. In the method, venous compression and/or expansion in a mammal in an area of a muscle having a symptom associated with exertional compartment syndrome is evaluated by comparing venous flow at rest and after stress on the muscle. An anaesthetic is used to block a nerve supplying motor function to the muscle causing compression of a blood vessel. The mammal is evaluated after the block of the nerve to determine if the symptom associated with exertional compartment syndrome is alleviated. | 2014-04-03 |
20140093456 | TUMOR MODEL SYSTEM USEFUL TO STUDY MULTISTAGE CANCER - The present invention relates to a method of developing a Tumor Model System. The invention deals with a tumor model system with adhesion deprived cells. This observation provides a new method for primary detection of transformation of adhesion-deprived cells and tumorigenicity. The adhesion-deprived cells are capable of metastasizing at distant sites and the model system includes both the tumor formation and metastasis. | 2014-04-03 |
20140093457 | Compositions, methods and kits for remineralization and inhibition of dental caries in teeth - Methods, compositions and kits are provided for enhancing remineralization of a tooth or bone containing hydroxyapatite and inhibiting caries progression or loss of hydroxyapatite using a bisphosphonate or pyrophosphonate. The tooth or tooth surface contains a trauma or defect, for example the tooth contains a caries that is identified using a detectable probe. The bisphosphonate or pyrophosphonate is contacted to the tooth and/or oral cavity and binds to the hydroxyapatite material in the tooth or bone and prevents loss of hydroxyapatite material or strengthens the hydroxyapatite. The amount and extent of enhanced remineralization or of inhibition of caries progression and loss of hydroxyapatite are determined by techniques including photography, light microscopy and fluorescence microscopy. | 2014-04-03 |
20140093458 | IN VIVO SELECTION OF THERAPEUTICALLY ACTIVE ANTIBODIES - The present invention relates to non-invasive methods of in vivo selecting an antibody against a desired target on the surface of a mammalian cell of a subject by applying near-infrared fluorescence imaging (NIRF) as well as uses of NIRF in such methods. In addition, kits for the use in these methods comprising a panel of potentially therapeutic effective fluorescence labeled antibodies and means for NIRF imaging are provided. | 2014-04-03 |
20140093459 | NOVEL COMPOUND - Methods to to enhance solubility of butyl methoxydibenzoylmethane and/or bis-ethylhexyloxyphenol methoxyphenyl triazine in a cosmetic oil suitable as a solvent for butyl methoxydibenzoylmethane and/or bis-ethylhexyloxyphenol methoxyphenyl triazine are provided which include incorporating a solubility enhancing effective amount of a polyglycerol based UV filter in such cosmetic oil. | 2014-04-03 |
20140093460 | NAIL ENAMEL COMPOSITION - A nail enamel composition has a film-forming mixture and an accelerator mixture. The film-forming mixture includes 9-28% nitrocellulose, by weight, in a suitable solvent. The accelerator mixture includes acetone and/or ethyl acetate. The composition further includes less than 1% cyanoacrylate, by weight. The nail enamel composition is substantially free of graphite fibers. | 2014-04-03 |
20140093461 | SOLID COSMETIC COMPOSITION IN COMPACT POWDER FORM - The present invention relates to a solid cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: —a pulverulent phase in an amount of greater than or equal to 35% by weight relative to the total weight of the composition, —a liquid fatty phase comprising at least one non-volatile oil, and—at least one amorphous hydrocarbon-based block copolymer. The present invention also relates to a process for coating the face, and in particular the eyelids, with the said cosmetic composition. | 2014-04-03 |
20140093462 | Lip Cosmetics - The present invention provides a lip cosmetic that has excellent secondary adhesion resistance effect immediately after the application and is excellent in gloss and stability. The lip cosmetic of the present invention is characterized by comprising the following (a) and (b), wherein the blending quantity of (b) is 20 to 70 mass %: | 2014-04-03 |
20140093463 | USE OF CHARGED SURFACTANTS FOR REDUCING TEXTILE STAINING BY ANTIPERSPIRANTS - Disclosed is a method of reducing or avoiding staining in or on clothing caused by a cosmetic or dermatological preparation comprising one or more antiperspirant substances and/or of improving the ability of stains in or on clothing which are caused at least in part by said preparation to be washed out from the clothing. The method comprises including in the preparation one or more cationic surfactants. | 2014-04-03 |
20140093464 | USE OF CHARGED SURFACTANTS FOR REDUCING TEXTILE STAINING BY ANTIPERSPIRANTS - Disclosed is cosmetic or dermatological preparation which is present as an aerosol spray and comprises one or more antiperspirant substances and one or more cationic surfactants. | 2014-04-03 |
20140093465 | Mascara For Use With A Vibrating Applicator: Compositions And Methods - Compositions for use with a mascara applicator with vibrating applicator head. The frequency, amplitude and geometry of the vibrating head are sufficient to significantly alter the rheological properties of thixotropic and anti-thixotropic mascara compositions, including an effect that persists after the vibration has stopped. The mascara may be manipulated for improved results, greater flexibility in formulation, benefits in manufacture, as well as other benefits. | 2014-04-03 |
20140093466 | HAIR CARE COMPOSITIONS AND METHODS OF USE - Hair care compositions including from about 0.005% to about 5% apigenin; from about 0.15% to about 12% of a solubilizing agent, wherein the solubilizing agent comprises an amine functional group; and at least about 20 weight percent of an aqueous carrier, where the composition has a pH ranging from about 3 to about 10, and methods of making the same are provided. These hair care compositions can be applied to any area of the scalp or hair where healthier hair appearance is desired. | 2014-04-03 |
20140093467 | STYLING AGENTS HAVING MAXIMUM HOLD - Agents for the temporary shaping of keratinic fibers include in a cosmetically acceptable carrier—relative in each case to the weight thereof—1 to 20 wt. % of at least one crosslinked, amphiphilic, anionic polymer comprising at least one structural unit of formula (I) as described herein and at least one structural unit of formula (II) as described herein, and 1 to 20 wt. % of at least one uncrosslinked, anionic polymer comprising at least one structural unit of formula (III) as described herein and at least one structural unit of formula (IV) as described herein, and 1 to 40 wt. % of at least one fixing non-ionic polymer from the group comprising (c1) non-ionic polymers having at least one structural element of formula (N5) as described herein, (c2) homopolymers and non-ionic copolymers of N-vinylpyrrolidone, and (c3) non-ionic copolymers of isobutene. | 2014-04-03 |
20140093468 | STYLING AGENTS WITH AN INTERESTING TEXTURE - Agents for the temporary shaping of keratinic fibers are characterized by a pleasant product feel, light consistency and a lightweight application. The agents include in a cosmetically acceptable carrier, relative in each case to the total agent, 0.1 to 15 wt. % of monoesters of optionally alkylated sugars with C | 2014-04-03 |
20140093469 | SHINE-PRODUCING HAIR-STYLING PRODUCT WITH A STRONG HOLD, PROVIDING HAIR WITH A PLEASANT FEEL - Agents for treating keratin-containing fibers, in particular human hair, containing, in a cosmetically acceptable carrier: at least one anionic setting copolymer encompassing at least one structural unit of formula (I) and at least one structural unit of formula (II) and at least one structural unit of formula (III), in which R | 2014-04-03 |
20140093470 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR RESTORATION, COMPRISING SOY EXTRACT - Disclosed is a composition for preventing hair loss or promoting hair restoration and for enhancing hair health, the composition comprising an active ingredient in the form of soy extract extracted using a C | 2014-04-03 |
20140093471 | AIR AND FABRIC FRESHENER - The present invention relates to a stable, aqueous freshener composition for the reduction or elimination of malodors in air and on fabrics. The composition comprises from about 0.1% to about 3.0% by weight, hydrogen peroxide as a malodor oxidant; an effective level of undecylenic acid (and/or derivative thereof) as a malodor absorber preblended with a fragrance; a surfactant to solubilize the fragrance/malodor absorber blend; an acid based stabilizer in a range from about 0.008% to about 0.60% by weight; an optional pH buffer; and an aqueous carrier. The composition can be delivered via a spray dispenser for treatment of indoor air and fabrics. The composition has a pH of less than about 6 and does not contain ingredients known to soil, stain or damage fabrics. When applied as a fine mist, the composition delivers effective control of a broad range of malodors, while remaining imperceptible on surfaces when dry. | 2014-04-03 |
20140093472 | L-HISTIDINE IN OPHTHALMIC SOLUTIONS - The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight L-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye. | 2014-04-03 |
20140093473 | AMPHIPHILIC LINEAR PEPTIDEPEPTOID AND HYDROGEL COMPRISING THE SAME - The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid. | 2014-04-03 |
20140093474 | CONTROL OF INSECT PESTS THROUGH RNAI OF PHEROMONE BIOSYNTHESIS ACTIVATING NEUROPEPTIDE RECEPTOR - Disclosed are dsRNA constructs and methods to control insects via double stranded RNA interference of insect PBAN receptor genes. | 2014-04-03 |
20140093475 | Suppression of Bone Loss by Introducing FoxP3+ CD8 T-cells (TcREG) - Systems and methods for inhibiting bone loss using FoxP3+ CD8 T-cells (Tc | 2014-04-03 |
20140093476 | METHODS FOR TREATING PAIN - Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions. | 2014-04-03 |
20140093477 | MODULATING BACTERIAL MAM POLYPEPTIDES IN PATHOGENIC DISEASE - The disclosure relates to methods and compositions for preventing or inhibiting pathogenic bacterial infections in a subject caused by pathogenic bacteria expressing a multivalent adhesion molecule (MAM) polypeptide by administering to a subject a composition comprising a MAM polypeptide or a non-pathogenic bacterium expressing a MAM polypeptide, or a combination thereof. | 2014-04-03 |
20140093478 | GUT MICROBIOME AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR AN OBESITY RELATED DISORDER - The present invention relates to the gut microbiome as a biomarker and therapeutic target for energy harvesting, weight loss or gain, and/or obesity in a subject. In particular, the invention provides methods of altering and monitoring the relative abundance of | 2014-04-03 |
20140093479 | PROBIOTIC BACTERIAL STRAINS AND SYMBIOTIC COMPOSITION CONTAINING THE SAME INTENDED FOR INFANT FOOD - Selection of probiotic strains belonging to the genus | 2014-04-03 |
20140093480 | Novel Mensenchymal Stem Cells And Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 2014-04-03 |
20140093481 | PRODUCTION OF DENTIN, CEMENTUM AND ENAMEL BY CELLS - One aspect provides a method of forming a mineralized material by co-culturing a epithelial cell, such as ameloblasts, and mesenchymal cells, such as osteoblasts or odontoblasts, in a mineral-stimulating medium. Another aspect provides matrix seeded with epithelial cells and mesenchymal cells and infused with a mineral-stimulating medium capable of forming a mineralized material in the matrix. Methods of manufacturing such compositions and methods of treating mineralization-related conditions are also provided. | 2014-04-03 |
20140093482 | METHODS AND APPARATUSES FOR ISOLATING AND PREPARING STEM CELLS - The present invention relates to a method of preparing a population of stem cells for autologous implantation to a subject. The cells are activated by irradiating the cells with one or more wavelengths of yellow and red and/or green light. In particular, the cells are irradiated with 575-595 nm (5-20 mW), and 630-635 nm or 660-670 nm (10-100 mW) and/or 510-540 nm (10-60 mW) of monochromatic light for 30-60 mins. Preferably the stem cells are adipose-derived stem cells. Also the invention relates to therapeutic applications of the activated stem cells. | 2014-04-03 |
20140093483 | COMPOSITION OF CULTURED GRAPE CELLS - A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless cultivars or grape seed coat. | 2014-04-03 |
20140093484 | Use of Dextran Sulfate - A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof. | 2014-04-03 |
20140093485 | THYMIDYLATE KINASE FUSIONS AND USES THEREOF - The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer. | 2014-04-03 |
20140093486 | METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS AND ITS APPLICATIONS - The present invention relates to a novel method for preparing induced pluripotent stem cells (iPSCs) by introducing three genes, Oct3/4, Sox2, and Parp1, into somatic cells. The present invention also relates to the iPSCs produced by the aforementioned method. Also provided is a method of rejuvenating cells by use of a PARylated protein or an enzyme with PARylation activity. Further provided is a method for inducing the secretion of interferon-γ inducible protein-10 (IP-10) comprising administering to a subject in need thereof an effective amount of iPSCs or iPSC-CM. | 2014-04-03 |
20140093487 | SYNERGISTIC ANTIMICROBIAL EFFECT - The present invention is related to the field of bioprotection, in particular to an antimicrobial composition comprising a | 2014-04-03 |
20140093488 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS - Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. | 2014-04-03 |
20140093489 | NUTRITIONAL SUPPLEMENTS FOR EYE HEALTH AND RELATED METHODS - A nutritional or dietary supplement composition that strengthens and promotes a general eye health benefit for aging adults, including retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. | 2014-04-03 |
20140093490 | GLUTAMATE RELEASE FROM ASTROCYTE - The present invention investigate the two modes of glutamate release and the releasing rate of glutamate, and thus can provide a useful technique for neuron protection and acceleration of neurotransmission by controlling the glutamate release in astroctye. Thus, the present invention provides an inhibitor of the fast-mode release and/or the slow-mode release of astrocytic glutamate, a screening method of the inhibitor and a pharmaceutical composition or method of ameliorating, preventing and/or treating the disease associated with the over-release of glutamate via the Ca | 2014-04-03 |
20140093491 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII. | 2014-04-03 |
20140093492 | METHOD FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 2014-04-03 |
20140093493 | METHOD AND FORMULATION FOR REDUCING AGGREGATION OF A MACROMOLECULE UNDER PHYSIOLOGICAL CONDITIONS - The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of certain cyclodextrins (CDs). The invention also provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule and pharmaceutical formulations for such administration. Further the invention provides methods of treating a CD20 positive cancer or an autoimmune disease, comprising administering a humanized anti-CD20 antibody in a pharmaceutical formulation of the invention. The invention further provides an in vitro dialysis method to evaluate the ability of an excipient to reduce aggregation of an antibody or other macromolecule under physiological conditions. | 2014-04-03 |
20140093494 | ALPHA SYNUCLEIN TOXICITY - It is demonstrated that alpha synculein toxicity such as α-synuclein mediated cell death, and alpha synuclein induced reactive oxygen species (ROS) in a cell requires proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. In view of these observations, compositions and methods for inhibition of α-synuclein toxicity are provided. The inhibiting α-synuclein toxicity can be used in methods for the treatment of synucleinopathies, such as Parkinsons disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atroypy (MSA) and the manufacture of medicaments for such treatment. In particular, pharmaceutical compositions containing inhibitors of endonuclease G, and their use in the treatment of synucleinopathies such as Parkinson's disease, dementia with Lew bodies, pure autonomic failure, and multiple system atrophy and the manufacture of medicaments for such treatment are presented. In addition, methods for the identification of compounds for attenuating the synuclein toxicity are also provided. | 2014-04-03 |
20140093495 | NOVEL MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided. | 2014-04-03 |
20140093496 | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY - An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of FcγRIIa, types H and R, and having enhanced FcγRIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of FcγRIIa and enhancing the FcγRIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R. It is also found that a polypeptide containing an antibody Fc region that contains an alteration of substituting Pro at position 238 (EU numbering) with Asp and several other alterations, enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R. | 2014-04-03 |
20140093497 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies. | 2014-04-03 |
20140093498 | PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2 / DLL4 BINDERS AND ANTI-VEGF-R AGENTS - The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/DII4 binders and anti-VEGF-R agents for use in treating diseases like cancer and ocular diseases. | 2014-04-03 |
20140093499 | PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2 / DLL4 BINDERS AND ANTI-VEGF AGENTS - The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/Dll4 binders and anti-VEGF agents for use in treating diseases like cancer and ocular diseases. | 2014-04-03 |
20140093500 | RSV SPECIFIC BINDING MOLECULE - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. | 2014-04-03 |
20140093501 | Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus - This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection. | 2014-04-03 |
20140093502 | Immunosuppressive Combination and Its Use in the Treatment or Prophylaxis of Insulin-producing Cell Graft Rejection - A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection. | 2014-04-03 |
20140093503 | Taxane and Abeo-Taxane Analogs - The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the abeo-taxanes. | 2014-04-03 |
20140093504 | Anti-Ricin Antibodies And Uses Thereof - The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis. | 2014-04-03 |
20140093505 | Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof - The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R | 2014-04-03 |
20140093506 | ANTI-FUNGAL-AGENTS - The present application relates to methods for reducing growth of a fungus having a coordination complex formed at the C-terminus of its dicer (dicer 1, ribonuclease type III) between an anion and the amino acids corresponding to the amino acids C1275, H1312, C1350 and C1352 of Dcr1 of | 2014-04-03 |
20140093507 | Diagnostics and Therapeutics for Diseases Associated With G-Protein Coupled Receptor AdipoR2 (AdipoR2) - The invention provides human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds. | 2014-04-03 |
20140093508 | Toll-Like 3 Receptor Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 2014-04-03 |
20140093509 | Screening Method for the Identification of Agents Capable of Activating CD4+CD25+ Regulatory T-Cells Through Interactions with the HIV-1 GP120 Binding Site on CD4 - The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction. | 2014-04-03 |
20140093510 | CHLAMYDIA ANTIGENS - The invention provides | 2014-04-03 |
20140093511 | OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF - The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided. | 2014-04-03 |
20140093512 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN AND A SUGAR SELECTED FROM SUCROSE AND TREHALOSE - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 2014-04-03 |
20140093513 | METHODS OF LOWERING PROPROTEIN CONVERSATE SUBTILISIN/KEXIN TYPE 9 (PCSK9) - The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases. | 2014-04-03 |
20140093514 | MAGEA3 BINDING ANTIBODIES - The present invention relates to MAGEA3 binding antibodies. | 2014-04-03 |
20140093515 | PROCESS OF AFOD AND AFCC AND MANUFACTURING AND PURIFICATION PROCESSES OF PROTEINS - Manufacturing and purification processes of proteins, KH 1-through KH-52, and more KH proteins are being discovered in good healthy cells—named KH CELLS. KH CELLS are good healthy cells in which the RNA synthesizes good proteins that: 1) Send signal to the damaged, sick, and bad cells that triggers that synthesis of good proteins that transform these cells to become GOOD healthy cells; 2) Send signal to the other currently undamaged cells to synthesis of good proteins to protect them from being damaged, infected and prone to DNA and other cellular alterations; and 3) Send signal to the body to produce new cells that are healthy and forbid them from being affected by intra- and extracellular damaging signals. The mechanism that governs these processes is that the KH good healthy cells provide innate good signals that make good proteins to boost the immune system. | 2014-04-03 |
20140093516 | HUMAN ANTIBODIES THAT BIND THE P40 SUBUNIT OF HUMAN IL-12/IL-23 AND USES THEREFOR - The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23. | 2014-04-03 |
20140093517 | OXIDIZED LDL AS A BIOMARKER FOR NEUROLOGICAL COMPLICATIONS OF PREGNANCY - Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided. | 2014-04-03 |
20140093518 | Chemically Programmed Vaccination - Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound. | 2014-04-03 |
20140093519 | METHODS FOR PANCREATIC TISSUE REGENERATION - Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or conditions where enhancement of pancreatic progenitor cells for cell replacement therapy is desirable, including, e.g., diabetes and conditions that result in loss of all or part of the pancreas. | 2014-04-03 |
20140093520 | VEGF-D/VEGFR2/3-Mediated Regulation of Dendrites - The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and/or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and/or disease-related cognitive dysfunctions, or for impairing the memory of a subject. Finally, the present invention relates to recombinant VEGFD (rVEGFD) for use in the treatment of age- and/or disease-related cognitive dysfunctions. | 2014-04-03 |
20140093521 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 2014-04-03 |
20140093522 | BIO-ORTHOGONAL DRUG ACTIVATION - The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives. | 2014-04-03 |
20140093523 | Anti-Integrin Immunoconjugates, Methods and Uses - The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog. | 2014-04-03 |
20140093524 | MODIFIED CHAPERONIN 10 - The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity. | 2014-04-03 |
20140093526 | Preparation of Neutralizing Antibody to Human Herpesvirus 6 Glycoprotein Q1 and Analysis Thereof - The present invention addresses the problem of providing a vaccine which as yet has not been provided for the disease HHV-6B, which is the cause of exanthema subitum in infants, and the problem of providing an effective screening method for other therapeutic drugs. The above-mentioned problems are solved by providing an epitope specific to HHV-6B, of the amino acid sequence (QALCEGGHVFYNP) represented by positions 484 to 496 of SEQ ID NO: 2 or a modified sequence thereof, wherein the epitope either has a sequence comprising at least five consecutive amino acids including at least E, or a sequence that preserves the 487 | 2014-04-03 |
20140093527 | COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT - The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof. | 2014-04-03 |
20140093528 | DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION - Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1. | 2014-04-03 |
20140093529 | IMMUNOGENIC COMPOSITION - The present invention relates to fusion proteins comprising fragments of toxin A and toxin B from | 2014-04-03 |
20140093530 | MALARIA VACCINES - The present invention relates to a synthetic antigenic sequence which represents a combination of epitope-containing sequences from the highly polymorphic block 2 repeat region of K1-type | 2014-04-03 |
20140093531 | LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE - Substantially purified salivary | 2014-04-03 |
20140093532 | Immunogenic Compositions In Particulate Form And Methods For Producing The Same - The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. Also provided is a recombinant polypeptide comprising (A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused to (B) an oligomerization domain (OMD), said oligomerization domain being fused via (C) a linker domain to (D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium. | 2014-04-03 |
20140093533 | POLYPEPTIDES AND VECTORS FOR TARGETING HER2/NEU EXPRESSING CELLS AND USES THEREOF - Various aspects of the invention provide for capsids, parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing polypeptides in which the sequence YCDGFYACYMDV (SEQ ID NO: 3) has been substituted into the VP2 loop of the B19 capsid protein. Polypeptides in which the sequence YCDGFYACYMDV (SEQ ID NO: 3) has been substituted into the VP2 loop of the B19 capsid protein are also provided (e.g., SEQ ID NO: 2). Other aspects of the invention provide capsids, parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing a polypeptide comprising SEQ ID NO: 2. Also provided in various aspects of the invention are pharmaceutical compositions and methods of delivering therapeutic agents and/or reporter peptides/proteins to target cells. Finally, methods of treating diseases characterized by cells expression HER2/neu receptors are also provided. | 2014-04-03 |
20140093534 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES - Provided herein are | 2014-04-03 |
20140093535 | COMBINED VACCINES FOR PREVENTION OF PORCINE VIRUS INFECTIONS - The present disclosure provides vaccine compositions comprising a PRRSV vaccine and a second porcine vaccine, which are substantially free from immuno-inhibition against each other. The second porcine virus vaccine can be CSFV and/or PRV. The preparation methods for the vaccines and the formulations are also provided. The vaccine compositions provided herein confer protective immunity to pigs against porcine reproductive and respiratory syndrome, classical swine fever, and/or pseudorabies. | 2014-04-03 |
20140093536 | Compositions And Methods For Treatment Of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2014-04-03 |
20140093537 | IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND METHODS OF ADMINISTERING THE SAME - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of administering the same (e.g., via a heterologous prime/boost protocol (e.g., utilizing the same nanoemulsion in each the prime and boost administrations)) to induce immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 2014-04-03 |
20140093538 | Method for Priming of T Cells - The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof. | 2014-04-03 |
20140093539 | PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg. | 2014-04-03 |
20140093540 | IMMUNOGENIC COMPOSITIONS AND EXPRESSION SYSTEMS - Immunogenic compositions and vaccines against Plasmodial infection comprising an Rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are Rh5 polypeptides or fragments or variants thereof capable of binding CD147 and conferring protection against infection and/or disease caused by multiple Plasmodial strains or Plasmodial species, inhibitors of the interaction between Rh5 and CD147 and methods for producing polypeptides in a mammalian expression system. | 2014-04-03 |
20140093541 | TREATMENT FOR PEANUT ALLERGY - The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years. | 2014-04-03 |
20140093542 | REGULATORS OF NFAT AND/OR STORE-OPERATED CALCIUM ENTRY - Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca | 2014-04-03 |
20140093543 | METHOD AND VACUUM CONTAINER FOR PREPARING A BONE GRAFT - A vacuum container supports a cancellous device fully immersed within a solution of a bone growth promoting substance in a sealed chamber. The solution may include one of a Demineralized Bone Matrix (DBM) solution, a morphegenic protein solution, or a stem cell solution. A vacuum creating device is in fluid communication with the sealed chamber, and is operable to remove air from within the sealed chamber to create a vacuum therein. Removing air from the sealed chamber also removes air from a plurality of voids in the cancellous device, which allows the solution to fill the voids and saturate the cancellous device in preparation for use as a bone graft. | 2014-04-03 |